drugset / Trial / NCT00960362
An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)
RandomizedSingle-groupDouble-blindTreatment
Summary
This trial is conducted in North America. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic and signs of bioactivity of increasing single doses of AGS-009 in patients with systemic lupus erythematosus (SLE).
Timeline
- Start
- 2009-07
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGS-009 | Unknown | 0.01 mg/kg | Intravenous |
| Subject | AGS-009 | Unknown | 0.1 mg/kg | Intravenous |
| Subject | AGS-009 | Unknown | 0.6 mg/kg | Intravenous |
| Subject | AGS-009 | Unknown | 3 mg/kg | Intravenous |
| Subject | AGS-009 | Unknown | 10 mg/kg | Intravenous |
| Subject | AGS-009 | Unknown | 30 mg/kg | Intravenous |